Company intelligence / Profile preview

Brevitest Technologies

Houston, Texas, United States6sense.com ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

The company has commercialized rapid point-of-care tests for drugs of abuse and cardiac markers in forensic settings, with successful grant-funded development and validation studies. Its COVID IgG antibody test received FDA permission for commercial distribution in the US during the pandemic.

Therapeutic areas: PsychiatryCardiovascularNeurologyInfectious Diseases
Modalities: Device (point-of-care analyzer)Diagnostic assay platform (ELISA-based)
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

BreviTest Portable Analyzer

Pre-clinical

Indications: COVID-19, Infectious diseases

1 more asset in the full pipeline.

Request access →

Partnerships

National Institute on Drug Abuse/National Institutes of Health SBIR program funding partner

Beyond the preview

Go deeper on Brevitest Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brevitest Technologies.

Explore the full profile